title: Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.
abstract: Comparison of lipid, lipoprotein and apolipoprotein levels was made between 3 groups: continuous ambulatory peritoneal dialysis patients (n = 5); haemodialysis patients (n = 15) and normals (n = 31). Continuous ambulatory peritoneal dialysis (CAPD) patients showed significantly elevated total cholesterol, low density lipoprotein (LDL)-cholesterol and apolipoprotein B (apo B) levels compared with haemodialysis and normal groups. Both CAPD and haemodialysis (HD) showed reduced levels of high density lipoprotein (HDL)-cholesterol and apolipoprotein A-I (apo A-I). Measurement of apo A-I and apo B in dialysate during a 6 h CAPD session indicated significant losses of apo A-I to dialysate with negligible losses of apo B. Grossly elevated apo B and reduced apo A-I indicates that CAPD patients are at increased risk of coronary heart disease and that their risk is probably greater than for haemodialysis patients.
authors: Department of Chemical Pathology, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
authors: J
authors: J
authors: Steele
authors: T
authors: T
authors: Billington
authors: E
authors: E
authors: Janus
authors: J
authors: J
authors: Moran
mesh_terms: D001054:Apolipoproteins A / Q000172:deficiency*; D001055:Apolipoproteins B / Q000172:deficiency*; D001161:Arteriosclerosis / Q000209:etiology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008074:Lipoproteins / Q000172:deficiency*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008074:Lipoproteins